United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
1996_register
executive
2010-09-24
article
National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Fusion Proteins That Include Antibody and Non-Antibody Portions
Notices
D09002ee1be02ac33
D09002ee1be02acdf
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
The Department of Health and Human Services (DHHS) seeks one or more companies that can collaboratively pursue the pre-clinical and clinical development of Fusion Proteins That Include Antibody and Non- Antibody Portions. The following disease states are of interest: neoplasia, arteriosclerosis, tumor vascularization, fibrotic diseases, psoriasis and wound healing. The National Cancer Institute, Laboratory of Cellular and Molecular Biology has developed an assay system to identify receptor agonists and antagonists using fusion protein technology. The selected sponsor will be awarded a CRADA with the National Cancer Institute for the co-development of agents identified using the fusion protein technology.
61 FR 58572
https://www.govinfo.gov/app/details/FR-1996-11-15/96-29346
96-29346
fr15no96-104
https://www.govinfo.gov/app/details/FR-1996-11-15/96-29346
https://www.govinfo.gov/content/pkg/FR-1996-11-15/html/96-29346.htm
https://www.govinfo.gov/content/pkg/FR-1996-11-15/pdf/96-29346.pdf
2 p.
58572
58573
61 FR 58572
National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Fusion Proteins That Include Antibody and Non-Antibody Portions; Federal Register Vol. 61, Issue
NOTICE
96-29346
DEPARTMENT OF HEALTH AND HUMAN SERVICES
96-29346
Notice.
The Department of Health and Human Services (DHHS) seeks one or more companies that can collaboratively pursue the pre-clinical and clinical development of Fusion Proteins That Include Antibody and Non- Antibody Portions. The following disease states are of interest: neoplasia, arteriosclerosis, tumor vascularization, fibrotic diseases, psoriasis and wound healing. The National Cancer Institute, Laboratory of Cellular and Molecular Biology has developed an assay system to identify receptor agonists and antagonists using fusion protein technology. The selected sponsor will be awarded a CRADA with the National Cancer Institute for the co-development of agents identified using the fusion protein technology.
In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than [FR: insert date 60 days after date of publication]. Respondents will then be provided an additional 30 days for the filing of formal proposals.
Federal Register
Vol. 61, no. 222
Office of the Federal Register, National Archives and Records Administration
1996-11-15
continuing
daily
deposited
born digital
179 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-1996-11-15
P0b002ee180a27e4b
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr15no96
https://www.govinfo.gov/app/details/FR-1996-11-15
https://www.govinfo.gov/content/pkg/FR-1996-11-15/pdf/FR-1996-11-15.pdf
fdlp
58457
58622
DGPO
2010-09-24
2023-05-06
FR-1996-11-15
machine generated
eng
FR
FR-1996-11-15
61
222